A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

PHASE3CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 29, 2016

Study Completion Date

March 29, 2016

Conditions
LeiomyomaUterine Hemorrhage
Interventions
DRUG

Ulipristal acetate (UPA)

UPA tablet

DRUG

Placebo

Matching placebo tablet.

Trial Locations (28)

19046

Watson Investigational Site 119, Jenkintown

20036

Watson Investigational Site 114, Washington D.C.

27103

Watson Investigational Site 109, Winston-Salem

27607

Watson Investigational Site 121, Raleigh

29572

Watson Investigational Site 108, Myrtle Beach

30338

Watson Investigational Site 103, Atlanta

30342

Watson Investigational Site 123, Atlanta

30912

Watson Investigational Site 111, Augusta

32806

Watson Investigational Site 104, Orlando

Watson Investigational Site 120, Orlando

33176

Watson Investigational Site 130, Miami

33461

Watson Investigational Site 122, Lake Worth

33765

Watson Investigational Site 106, Clearwater

34652

Watson Investigational Site 105, New Port Richey

37404

Watson Investigational Site 101, Chattanooga

38119

Watson Investigational Site 126, Memphis

43231

Watson Investigational Site 107, Columbus

46112

Watson Investigational Site 131, Brownsburg

66218

Watson Investigational Site 129, Shawnee Mission

68701

Watson Investigational Site 110, Norfolk

70006

Watson Investigational Site 132, Metairie

80209

Watson Investigational Site 112, Denver

80228

Watson Investigational Site 115, Lakewood

83404

Watson Investigational Site 124, Idaho Falls

85710

Watson Investigational Site 125, Tucson

87109

Watson Investigational Site 113, Albuquerque

92103

Watson Investigational Site 102, San Diego

06460

Watson Investigational Site 116, Milford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY